Skip to main content

Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.

Publication ,  Journal Article
Duvic, M; Martin, AG; Olsen, EA; Fivenson, DP; Prince, HM
Published in: Leuk Lymphoma
March 2013

This open-label phase III trial, a companion to an earlier placebo-controlled trial, evaluated safety and efficacy of denileukin diftitox (DD) in patients with cutaneous T-cell lymphoma (CTCL) who relapsed after responding to DD primary treatment in the earlier trial. Twenty relapsed patients (stages IA-III) received DD 18 μg/kg/day intravenously on days 1-5 of a 21-day cycle, for ≤ 8 cycles. Efficacy was assessed monthly during the first year then every 3 months. The overall response rate was 40%, mostly partial responses. Nine patients (all baseline stages ≤ IIA) experienced progression. Intent-to-treat median progression-free survival was 205 days, and median duration of response was 274 days. The most common adverse events were nausea, upper respiratory tract infections, fatigue and rigors. Three patients withdrew because of toxicity. This study showed that DD may provide clinically meaningful benefit in patients with CTCL who relapsed after initial response to DD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

March 2013

Volume

54

Issue

3

Start / End Page

514 / 519

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Skin Neoplasms
  • Remission Induction
  • Recurrence
  • Recombinant Fusion Proteins
  • Nausea
  • Middle Aged
  • Male
  • Lymphoma, T-Cell, Cutaneous
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Duvic, M., Martin, A. G., Olsen, E. A., Fivenson, D. P., & Prince, H. M. (2013). Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma, 54(3), 514–519. https://doi.org/10.3109/10428194.2012.720372
Duvic, Madeleine, Ann G. Martin, Elise A. Olsen, David P. Fivenson, and H Miles Prince. “Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.Leuk Lymphoma 54, no. 3 (March 2013): 514–19. https://doi.org/10.3109/10428194.2012.720372.
Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar;54(3):514–9.
Duvic, Madeleine, et al. “Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.Leuk Lymphoma, vol. 54, no. 3, Mar. 2013, pp. 514–19. Pubmed, doi:10.3109/10428194.2012.720372.
Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar;54(3):514–519.

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

March 2013

Volume

54

Issue

3

Start / End Page

514 / 519

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Skin Neoplasms
  • Remission Induction
  • Recurrence
  • Recombinant Fusion Proteins
  • Nausea
  • Middle Aged
  • Male
  • Lymphoma, T-Cell, Cutaneous
  • Kaplan-Meier Estimate